TABLE 1.
Demographic and baseline characteristics of all patients (n = 35)
| Characteristic | All patients (%) | With sarcopenia (%) | Without sarcopenia (%) | p‐value |
|---|---|---|---|---|
| Age, years | 0.413 | |||
| ≥70 | 13 (37.1) | 10 (76.9) | 3 (23.1) | |
| <70 | 22 (62.9) | 14 (63.6) | 8 (36.4) | |
| Gender | 0.298 | |||
| Male | 14 (40) | 11 (78.6) | 3 (21.4) | |
| Female | 21 (60) | 13 (61.9) | 8 (38.1) | |
| ECOG PS | 0.556 | |||
| 0–1 | 33 (94.3) | 22 (66.7) | 11 (33.3) | |
| ≥2 | 2 (5.7) | 2 (100) | 0 (0) | |
| EGFR mutation status | 0.476 | |||
| Exon 19 del | 8 (22.9) | 5 (62.5) | 3 (37.5) | |
| Exon 21 L858R | 15 (42.9) | 9 (60.0) | 6 (40) | |
| Uncommon mutations | 12 (34.2) | 10 (83.3) | 2 (16.6) | |
| Best response to afatinib | 1 | |||
| PR | 19 (54.3) | 13 (68.4) | 6 (31.6) | |
| SD | 16 (45.7) | 11 (68.8) | 5 (31.2) | |
| Weight loss within 3 months | 0.157 | |||
| ≥5% | 5 (14.3) | 5 (100) | 0 (0) | |
| <5% | 30 (85.7) | 19 (63.3) | 11 (36.6) | |
| Smoking status | ||||
| Smokers | 12 (34.3) | 9 (75.0) | 3 (25.0) | 0.709 |
| Non‐smokers | 23 (65.7) | 15 (65.2) | 8 (34.8) | |
| BMI status, kg/m2 | 0.064 | |||
| Underweight <18.5 | 3 (8.6) | 3 (100) | 0 (0) | |
| Normal 18.5–24.9 | 17 (48.5) | 14 (82.4) | 3 (17.6) | |
| Overweight ≥25 | 15 (42.9) | 7 (46.7) | 8 (53.3) | |
| BSA, m2 | 0.146 | |||
| ≤1.7 | 17 (48.6) | 14 (82.4) | 3 (17.6) | |
| >1.7 | 18 (51.4) | 10 (55.6) | 8 (44.4) |
Abbreviations: BSA, body surface area; CR, complete response; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PD, progressive disease; PR, partial response; PS, performance status; SD, stable disease.